DNAVaccine.com Presents: Designing an Epitope-Driven Vaccine for a “Stealth Virus” an H7N9 Case Study
November 21, 2013 – 2:53 pm
We are happy to once again bring you the opportunity to join us for a free online webinar. The upcoming webinar: ‘Designing an Epitope-Driven Vaccine for a "Stealth Virus" an H7N9 Case Study’ will be presented by Annie De Groot, MD of EpiVax, Inc. on December 6th. For additional information and to register please read on!
December 6, 2013 – 9:03 am
After 4 decades of vetting clinical trials of gene therapy for novel risks, it’s time to relax a bit, says a report issued today by an expert panel. But key government officials are greeting the recommendation with caution. Gene therapy has proved its value, and its leaders have managed ethics issues well, according to a panel convened by the Institute of Medicine (IOM) at the U.S. National Academies. The long-term hazards of gene therapy may not be clear yet, but the general risks seem no greater than in other areas of experimental medicine, the report says, so it’s time to phase out the U.S. outfit created in 1974 that’s dedicated to reviewing gene therapy, the Recombinant DNA Advisory Committee, or RAC.
December 5, 2013 – 10:02 am
A tuberculosis vaccine used in other parts of the world seemed, in a small new study, to be effective at preventing multiple sclerosis among people showing early signs of the condition. People showing early signs of multiple sclerosis -- a situation called clinically isolated syndrome -- who were randomized to received the Bacille Calmette-Guérin vaccine before undergoing multiple sclerosis treatment were less likely to develop multiple sclerosis, compared with those who received a placebo. The vaccine is used in other countries for tuberculosis prevention, though it is not used in the United States.
December 4, 2013 – 9:00 am
Pop a pill or be poked by a needle? Being able to orally deliver microscopic particles - know as nano-particles - loaded with medicine is a simple, convenient way to treat patients for various diseases, such as cancer or diabetes. But so far, nano-particles can only be given via injection since they have trouble being readily absorbed by the intestine, which limits their usefulness. Now a study led by researchers at Brigham and Women's Hospital (BWH) and Massachusetts Institute of Technology (MIT) is the first to report in the field of nano-medicine a new type of nano-particle that can be successfully absorbed through the digestive tract. The findings may one day allow patients to simply take a pill instead of receiving injections.
December 2, 2013 – 11:13 am
InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. "On this World AIDS Day, the advancement of VAC-3S into this Phase 2 study is an important step forward. We recognize we have much work to do towards the goal of durable treatments for patients and their families affected by HIV, and our company is rising to meet this challenge," said Shahin Gharakhanian, MD, InnaVirVax Chief Medical Officer.
December 2, 2013 – 11:01 am
December 1 is annual World AIDS Day; an opportunity to look at how medical research into fighting the disease is progressing. Today, 35 million people live with HIV, 25 million of whom are in Africa. It infects over two million people every year. Antiviral therapies have slowed down the progression of the disease, but these drugs are both expensive and toxic in the long run. Scientists have been searching for a vaccine for many years, and this research is at the heart of the Euroneut 41 program, involving 17 European partners. Its goal: to block HIV from entering the body by using an innovative vaccine based on GP41, a protein present in the virus. In France, the company Px Therapeutics has synthesized an enhanced version of this protein to obtain the best possible immune response.
November 29, 2013 – 9:54 am
Actor Ernie Lively suffered from a heart attack leaving him with far less energy than he used to have. Frustrated with his quality of life, Lively connected with Amit Patel, M.D., director of Clinical Regenerative Medicine and Tissue Engineering and an associate professor in the Division of Cardiothoracic Surgery at the University of Utah School of Medicine. Lively became a patient of Patel's in February, when Patel saved Lively's life after a complication with an angiogram left the actor with a severed aorta and problems with his coronary arteries. During the journey of his heart health issues, Lively peppered Patel with questions about one idea for helping to heal his ailing heart: stem cell therapy. This month, Lively got his wish when he became the first patient in the world to undergo retrograde gene therapy at University of Utah Hospital, a novel procedure designed to deliver stem cells to the heart to repair damaged muscle and arteries in the most minimally invasive way possible.
November 27, 2013 – 9:35 am
Baboons vaccinated against whooping cough could still carry the illness in their throats and spread it, research published in a science journal on Monday has found. The surprising new finding has not been replicated in people, but scientists say it may provide an important clue to a puzzling spike in the incidence of whooping cough across the country, which reached a 50-year high last year.
November 27, 2013 – 9:28 am
Dogs with the bleeding disorder hemophilia A have been successfully treated by gene therapy, according to US scientists. Two of three dogs given the experimental treatment remain free of severe symptoms more than two years on, they write in Nature Communications. Hemophilia A is a bleeding disorder which affects one in 10,000 men. Gene therapy may be suitable for human treatment for bleeding disorders in 10 years, says the Hemophilia Society.
November 26, 2013 – 11:30 am
If you’ve ever experienced the three-part Hepatitis B vaccine series, or – heaven forbid – the multi-jab rabies course, you know the joy of being turned into a human pincushion. Even if you don’t mind needles, each booster shot means another trip to the doctor’s office. But now scientists have come up with a remote-controlled vaccine delivery system that eliminates the need for follow-up injections. The new system uses a single shot to deliver a small and squishy, vaccine-containing hydrogel sphere to a spot beneath the skin. Then, instead of booster shots, swallowing a pill releases additional doses of vaccine. So in theory, instead of going back to the clinic for more syringe action, you could simply set a reminder on your phone and pop a pill.
November 25, 2013 – 9:50 am
Wits researchers Maria Papathanasopoulos and Dr Penny Moore will present a research lecture on their internationally recognised work at Wits University on Tuesday. Though condoms and male circumcision work to prevent HIV, about 1000 South Africans are still infected every day, said Papathanasopoulos.